Holmium (III)-doped multifunctional nanotheranostic agent for ultra-high-field magnetic resonance imaging-guided chemo-photothermal tumor therapy.
Humans
Female
Holmium
/ pharmacology
Photothermal Therapy
Contrast Media
/ pharmacology
Theranostic Nanomedicine
/ methods
Gadolinium
/ pharmacology
Phototherapy
/ methods
Breast Neoplasms
/ drug therapy
Magnetic Resonance Imaging
/ methods
Nanoparticles
/ chemistry
Doxorubicin
/ pharmacology
Hyperthermia, Induced
/ methods
Tumor Microenvironment
Breast cancer
Holmium (III)
Magnetic resonance imaging
Mesoporous polydopamine
Ultra-high-field
Journal
Acta biomaterialia
ISSN: 1878-7568
Titre abrégé: Acta Biomater
Pays: England
ID NLM: 101233144
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
22
05
2023
revised:
08
10
2023
accepted:
12
10
2023
medline:
27
11
2023
pubmed:
21
10
2023
entrez:
20
10
2023
Statut:
ppublish
Résumé
Ultra-high-field (UHF) MRI has shown great advantages over low-field magnetic resonance imaging (MRI). Despite being the most commonly used MRI contrast agents, gadolinium chelates perform poorly in high magnetic fields, which significantly weakens their T
Identifiants
pubmed: 37863345
pii: S1742-7061(23)00617-7
doi: 10.1016/j.actbio.2023.10.017
pii:
doi:
Substances chimiques
Holmium
W1XX32SQN1
Contrast Media
0
Gadolinium
AU0V1LM3JT
Doxorubicin
80168379AG
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
454-465Informations de copyright
Copyright © 2023. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no competing financial interests or personal ties that could appear to influence the work reported in this paper.